Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Adverse reactions
- Acronyms FROSTY
- Sponsors Aviragen Therapeutics
- 03 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Dec 2013 New trial record
- 23 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.